The SARS-CoV-2 main protease (Mpro) plays a crucial role in the production of functional viral proteins during infection and, like many viral proteases, can also target and cleave host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 can be recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification at the G26 position of mammalian tRNA, which promotes global protein synthesis, cellular redox homeostasis, and has links to neurological disability. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain that is required for tRNA modification activity in cells. Evolutionary analysis shows that the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 may be resistant to cleavage. In primates, regions outside of the cleavage site with rapid evolution could indicate possible adaptation to ancient viral pathogens. To visualize how Mpro recognizes the TRMT1 cleavage sequence, we determined the structure of a TRMT1 peptide in complex with Mpro, which reveals a substrate binding conformation distinct from the majority of available SARS-CoV-2 Mpro-peptide complexes. Kinetic parameters for peptide cleavage showed that while TRMT1(526-536) is cleaved much slower than the Mpro nsp4/5 autoprocessing sequence, it is proteolyzed with comparable efficiency to the Mpro-targeted nsp8/9 viral cleavage site. Mutagenesis studies and molecular dynamics simulations together indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis that follows substrate binding. Our results provide new information about the structural basis for Mpro substrate recognition and cleavage that could help inform future therapeutic design and raise the possibility that proteolysis of human TRMT1 during SARS-CoV-2 infection may impact protein translation or oxidative stress response and contribute to viral pathogenesis.

The SARS‐CoV‐2 main protease (MPro) is responsible for cleaving viral polypeptides to generate functional viral proteins, but like other viral proteases, MPro may also actively target and cleaa ve endogenous human host proteins during infection. Here we show that a human tRNA methyltransferase, TRMT1, can be recognized and cleaved by SARS‐CoV‐2 MPro. TRMT1 is a SAM‐dependent methyltransferase that installs the N2,N2‐dimethylguanosine (m2,2G) modification onto position G26 of human tRNAs. This abundant m2,2G modification is important for global protein synthesis, cellular redox homeostasis, and has been linked to neurodevelopmental defects. Early in the COVID‐19 pandemic, a host‐virus protein interaction map identified a putative interaction between SARS‐CoV‐2 MPro and human TRMT1. We carried out kinetic assays that show both a short peptide sequence in TRMT1 as well as endogenous, full‐length TRMT1 are actively cleaved by recombinant SARS‐CoV‐2 MPro in vitro. Cleavage of full‐length TRMT1 results in loss of its C‐terminal zinc finger domain thought to be critical for tRNA binding. Furthermore, we determined the co‐crystal structure of the human TRMT1 peptide in complex with SARS‐CoV‐2 MPro, which shows that the bound TRMT1 peptide substrate adopts a unique conformation in the protease active site. These results suggest that tRNA methyltransferase TRMT1 is a viable substrate for SARS‐CoV‐2 MPro, provide new structural insights into the diverse substrate recognition properties of the viral protease, and raise the possibility that TRMT1 cleavage during SARS‐CoV‐2 infection could contribute to downregulation of host protein synthesis or other phenotypes of viral infection.